122110-53-6

Basic information

• Product Name: pivalyloxymethyl butyrate
• Synonyms: pivalyloxymethyl butyrate;((2,2-Dimethylpropanoyl)oxy)methyl butanoate;Brn 4861411;Butanoic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester;Pivanex
• CAS NO: 122110-53-6
• Molecular Formula: C10H18 O4
• Molecular Weight: 202.25
• Mol File: 122110-53-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 249.3°Cat760mmHg
• Flash Point: 113°C
• Appearance: colorless or slightly yellow/
• Density: 1.008g/cm³
• Vapor Pressure: 0.0231mmHg at 25°C
• Refractive Index: 1.43
• Storage Temp.: ?20°C
• Solubility: DMSO: ≥10mg/mL
• CAS DataBase Reference: pivalyloxymethyl butyrate(CAS DataBase Reference)
• NIST Chemistry Reference: pivalyloxymethyl butyrate(122110-53-6)
• EPA Substance Registry System: pivalyloxymethyl butyrate(122110-53-6)

Safety Data

• WGK Germany: nwg
• Hazardous Substances Data: 122110-53-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H18O4/c1-5-6-8(11)13-7-14-9(12)10(2,3)4/h5-7H2,1-4H3

Upstream product

• 18997-19-8 Chloromethyl pivalate 
• 107-92-6 butyric acid 

Relevant articles and documents

Novel Anticancer Prodrugs of Butyric Acid. 2

The antitumor activity of novel prodrugs butyric acid was examined.The in vitro effect of the compounds on induction of cytodifferentiation and on inhibition of proliferation and clonogenicity showed that (pivaloyloxy)methyl butyrate (1a) (labeled AN-9) was the most active agent.SAR's suggested that its activity stemmed from hydrolytically released butyric acid.In vivo, 1a displayed antitumor activity in B16FO melanoma primary cancer model, manifested by a significant increase in the life span of the treated animals.Murine lung tumor burden, induced by injection of the highly metastatic melanoma cells (B16F10.9), was decreased by 1a.It also displayed a significant therapeutic activity against spontaneous metastases which were induced by 3LL Lewis lung carcinoma cells.Moreover, 1a has the advantage of low toxicity, with an acute LD50 = 1.36 +/- 0.1 g/kg (n = 5).These results suggest that 1a is a potential antineoplastic agent.

Methods of using carboxylic acid esters to increase fetal-hemoglobin levels

This invention relates to novel methods of increasing the level of fetal hemoglobin (HbF) in a subject and methods of treating, preventing or ameliorating β-globin or other HbF-related disorders by increasing the level of HbF in a subject in need of such treatment comprising administering one or more compounds of the Formulae (I), (II), or (III): (I) XCH2 --CHX--CHX--C(=O)--O--Z (II) CH3 --CO--CH2 --C(=O)--O--Z (III) CH3 --CH2 --CO--C(=O)--O--Z wherein: X is H, or one of X only may be OH; Z is --CHR--O--C(=O)R', --CHR--O--C(=O)--O--R', or STR1 R is H, alkyl, aryl, arylalkyl; and R' is alkyl, aminoalkyl, aralkyl, aryl, alkoxy, aralkoxy and aryloxy, in which aryl by itself, and aryl in aralkyl, aralkoxy and aryloxy are each selected from the group consisting of phenyl, naphthyl, furyl, or thienyl, each of which is unsubstituted or substituted by at least one substituent selected from the group consisting of alkyl, alkoxy, or halogen; and pharmaceutically acceptable salts and prodrugs thereof.